Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

NCT01762800 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: fluticasone propionate/salmeterol 50/250mcg
DRUG: fluticasone propionate/salmeterol placebo
DRUG: tiotropium bromide 18mcg
DRUG: tiotropium bromide placebo
DRUG: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg

Sponsor

GlaxoSmithKline